Health economic assessment of Ondexxya in life-threatening or uncontrolled bleeding

26 June 2020 - TLV has developed a health economic assessment for the regions of the drug Ondexxya (andexanet alfa).  ...

Read more →

Health economic assessment of Waylivra in familial chylomicronaemia

11 June 2020 - TLV has made a health economic assessment to the regions of the drug Waylivra (volansorsen).  ...

Read more →

Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)

29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) ...

Read more →

Health economic assessment of Spravato in treatment resistant depression

14 May 2020 - TLV has developed a health economic knowledge base for the regions for Spravato (esketamine).  ...

Read more →

Health economic assessment of gene therapy Zynteglo in transfusion-dependent beta-thalassemia

11 May 2020 - TLV has developed a health-economic knowledge base for the Zynteglo gene therapy (autologous CD34-positive cells expressing the ...

Read more →

Epidyolex is granted temporary subsidy

20 April 2020 - The TLV has decided that Epidyolex 100 mg /mL oral solution should be included in the ...

Read more →

Additional analysis of Kymriah in the treatment of patients with diffuse large-cell B-cell lymphoma

17 April 2020 - TLV has conducted an additional analysis of the earlier evaluation of Kymriah (tisagenleclucel) in the treatment ...

Read more →

Health economic assessment of Keytruda in combination with Inlyta in kidney cell cancer

31 March 2020 - TLV has developed a health economic knowledge base for the regions for combination treatment with the drugs ...

Read more →

Health economic assessment of Kyprolis in combination with Revlimid and dexamethasone

17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis ...

Read more →

Zejula is included in the high-cost protection with limitation

25 November 2019 - Zejula (niraparib) is included in the high-cost, limited-subsidy protection from December 1, 2019.  ...

Read more →

Health economic assessment of Tecentriq for triple negative breast cancer

8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab).  ...

Read more →

Joint evaluation report of sotagliflozin (Zynquista)

28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...

Read more →

Health economic assessment of Kymriah in diffuse large B-cell lymphoma

20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...

Read more →

TLV does not extend Hemlibra's current subsidy

18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients ...

Read more →

TLV publishes first joint report within the FINOSE co-operation

11 June 2019 - FINOSE is a collaboration between the HTA authorities, the pharmaceutical company Fimea (Finland), the Norwegian Medicines Agency, ...

Read more →